文献速递癫痫

利用至事件发生时间设计在抗癫痫药物临床试验中展示组水平和个体水平疗效

Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications.
PubMed 文献 · Neurology · 2024-07-25

本研究重新分析11项抗癫痫药物双盲安慰剂对照试验,比较至随机化前每月癫痫发作计数(T-PSC)设计与传统全长试验的主要疗效结论。结果显示11项试验中10项主要疗效结论一致,T-PSC时点观察到全长效应量的90%中位发作频率下降和85%的50%应答率,且盲法治疗时间至少缩短312参与者年。

要点

  • T-PSC设计在11项试验中10项主要疗效结论与传统设计一致,仅拉莫三嗪试验因安慰剂反应极高例外。
  • T-PSC时点中位发作频率下降达全长效应量的90%(95%CI 73%-113%),50%应答率达85%(95%CI 65%-110%)。
  • T-PSC设计使盲法治疗时间至少缩短312参与者年(占总时长40%),期间发生142,000次癫痫发作(占总发作60%)。

核心结论

  • 重新分析11项随机对照试验支持T-PSC设计用于新抗癫痫药物试验,观察至T-PSC足以证明疗效,并可能通过减少安慰剂和无效治疗暴露时间改善参与者安全。
  • 作者指出下一步是评估T-PSC是否足以通过不良事件评估安全性。

研究设计与样本

  • 重新分析11项双盲、安慰剂对照试验,涉及左乙拉西坦、布瓦西坦、拉考沙胺、托吡酯和拉莫三嗪,用于局灶性起源或全面性起源癫痫。
  • 共纳入3,619名参与者,比较T-PSC设计、至第二次发作时间和至第一次发作时间设计与全长试验的组水平和个体水平疗效。

主要发现

  • 11项试验中10项的主要疗效结论在T-PSC设计与传统设计下相同,例外为拉莫三嗪试验,其初始安慰剂反应非常高。
  • T-PSC时点观察到全长效应量的90%中位发作频率下降(95%CI 73%-113%)和85%的50%应答率(95%CI 65%-110%)。
  • 使用T-PSC设计,盲法治疗时间至少缩短312参与者年(占总时长40%),期间发生142,000次癫痫发作(占总发作60%)。
  • 至第一次或第二次发作时间设计再现了组水平效应量,但各试验的主要疗效结论和个体水平疗效对应性为一般至差。

局限性

  • 尽管分析了11项试验包括3,619名参与者,未观察到组水平效应量的显著降低,这与统计功效直接相关。
  • 作者指出下一步是评估T-PSC是否足以通过不良事件评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Participants with treatment-resistant epilepsy who are randomized to add-on placebo and remain in a trial for the typical 3 to 5-month maintenance period may be at increased risk of adverse outcomes. A novel trial design has been suggested, time to prerandomization monthly seizure count (T-PSC), which would limit participants' time on ineffective therapy. We reanalyzed 11 completed trials to determine whether the primary efficacy conclusions at T-PSC matched each of the original, longer trials. METHODS: A total of 11 double-blind, placebo-controlled trials of levetiracetam, brivaracetam, lacosamide, topiramate, and lamotrigine for either focal-onset or generalized-onset epilepsy were selected. We evaluated the group-level and individual-level efficacy of treatments including the median percent reduction (MPR) in seizure frequency and 50% responder rate (50RR) at T-PSC, time to second seizure, and time to first seizure compared with the full-length trial. RESULTS: The primary efficacy conclusions of 10 of the 11 trials would have been the same with a T-PSC design compared with the traditional design (the exception of lamotrigine had a very high initial placebo response). As a proportion of the full-length effect size, 90% of the MPR and 85% of the 50RR were seen at T-PSC (95% CI 73%-113% and 65%-110%, respectively). Using the T-PSC design, the time on blinded treatment was at least 312 participant-years shorter (40% of total duration) and 142,000 seizures occurred during this time (60% of total seizures). By contrast, the time to first or second seizure designs reproduced group-level effect size, but the primary efficacy conclusions of each trial and individual-level efficacy correspondence were fair to poor. DISCUSSION: These results support the use of this trial design for new epilepsy medication trials because this reanalysis of 11 randomized controlled trials demonstrated that observation until T-PSC was sufficient to demonstrate efficacy while potentially improving participant safety by reducing the time of exposure to placebo and inadequate treatment. Despite analysis of 11 trials including 3,619 participants, we did not observe a significant reduction in the group-level effect size, which is directly related to statistical power. The next step is to evaluate whether T-PSC is sufficient to evaluate safety as measured by adverse events.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Kerr WT, Kok N, Reddy AS, et al. Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications. Neurology. 2024. PMID: 39052963. doi:10.1212/WNL.0000000000209713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。